215 related articles for article (PubMed ID: 36622327)
1. Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer.
Nederlof I; Voorwerk L; Kok M
Clin Cancer Res; 2023 Jul; 29(13):2362-2370. PubMed ID: 36622327
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract][Full Text] [Related]
3. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
[TBL] [Abstract][Full Text] [Related]
4. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
6. Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.
Qian K; Liu Q
Transl Breast Cancer Res; 2023; 4():16. PubMed ID: 38751461
[TBL] [Abstract][Full Text] [Related]
7. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
11. Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.
Marhold M; Udovica S; Halstead A; Hirdler M; Ferner M; Wimmer K; Bago-Horvath Z; Exner R; Fitzal F; Strasser-Weippl K; Robinson T; Bartsch R
Oncoimmunology; 2023; 12(1):2275846. PubMed ID: 38025838
[TBL] [Abstract][Full Text] [Related]
12. Role of Immunotherapy in Breast Cancer.
Jacob SL; Huppert LA; Rugo HS
JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer.
Lopes AD; Galdino NAL; Figueiredo AB; Brianese RC; Morais KLP; De Brot M; Osório CABT; Teixeira-Carvalho A; Calsavara VF; Evangelista GFB; Alves NS; Makdissi FB; Sanches SM; Cordeiro de Lima VC; Carraro DM; Gollob KJ
Immunology; 2023 Jun; 169(2):229-241. PubMed ID: 36703241
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update.
Brown LC; Loi S
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S29-S33. PubMed ID: 34996667
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
16. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and breast cancer: an overview.
Mezni E; Behi K; Gonçalves A
Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
[TBL] [Abstract][Full Text] [Related]
20. The impact of chemotherapy and survival prediction by machine learning in early Elderly Triple Negative Breast Cancer (eTNBC): a population based study from the SEER database.
Huang K; Zhang J; Yu Y; Lin Y; Song C
BMC Geriatr; 2022 Apr; 22(1):268. PubMed ID: 35361134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]